A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-14. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Nick Raskulinecz − production, engineering Mike Terry − engineering Paul Fig − engineering John Lousteau − engineering Dave "Shirt" Nicholls − engineering on track 17 John Nicholson − drum technician Martin Connors − guitar technician on track 17 Randy Staub − mixing Rob Stefanson − assistant mixing Ted Jensen − mastering Hugh Syme − art direction, design, illustration Chapman Baehler − photography Bonus DVD credits
=== Sales === Garry's Mod sold 5,729 copies on its first day, 312,541 by December 2008, 770,628 by October 2010, 1 million by July 2011, 1.4 million by March 2012, 3.5 million by July 2013, 6 million by September 2014, 10 million by January 2016, 15 million by December 2019, 18,671,533 by December 2020, over 20 million by September 2021, and 25,560,290 at the game's eighteenth anniversary in November 2024. Newman estimated that, as of 2019, the game sold about 1.5 million copies annually. Sales of the game made for revenues of $3 million by December 2008, $22 million by March 2013, $30 million by February 2014, and US$119,836,074 by December 2020. The game's success allowed Facepunch to grow further, eventually branching out into other games, such as Rust. As of 2010, Garry's Mod is regularly among the then most-played games on Steam. Guinness World Records named it the best-selling PC-exclusive game ever in September 2024.
(CH2CH2)O + PCl3 → Cl–CH2CH2–OPCl2 2 (CH2CH2)O + PCl3 → (Cl–CH2CH2–O)2PCl 3 (CH2CH2)O + PCl3 → Cl–CH2CH2–O)3P The reaction product of ethylene oxide with acyl chlorides in the presence of sodium iodide is a complex iodoethyl ester:
Sources: en.wikipedia.org
The "fever" was noted to have started spreading since late April 2022, with Pyongyang being the centre of the spread. In line with the politburo decision, various enterprises continued to operate normally while organising emergency quarantine procedures. Various major projects, such as the 10,000 residential flats project, were to continue as before. Also, on 13 May, North Korean state media reported 6 deaths and 350,000 cases of fevers. On 14 May, an additional 174,440 cases of fever were reported, with 81,430 recoveries and 21 deaths. During the politburo conference, Kim Jong Un stated that the current situation was equal to the turmoil from the founding of the country, but the situation could be overcome with strong governance over the situation. According to the report, cases of the virus spreading between different regions had reduced. Emergency drug distribution was also ordered to commence in accordance with the anti-pandemic plan. On 17 May, it was reported that during the 24-hour period from 15 to 16 May, 269,510 cases of fever were recorded in the country, 170,460 people were cured, and 6 more died. The total officially reported number of cases reached 1,483,060. Out of these, 819,090 recovered from the illness, 663,910 were receiving treatment, and 56 died. While case numbers continued to rise in the provincial regions, case numbers began to fall in Pyongyang. According to KCTV, out of the 50 deaths reported up to 17 May, 25 were due to inappropriate usage of medicine. On 19 May, 262,270 cases of fever were reported, with one death.
Baiye, qianzhang, or gandoufu (百葉; 千張; 乾豆腐) is a very flat (about 2 mm thick) type of extra-firm tofu. It cannot be crumbled. The surface is filled with bulges arranged in a square grid from the muslin used to press it. It can be cut into long strings with a cross-section smaller than 2 mm × 2 mm and eaten in a way similar to gansi. It is also used to make：
Following his rookie season, Mizell married Nancy McAlpine. The couple had two sons: Wilmer David Jr. and James Daniel. Nancy died in 1990, and Mizell married Ruth Cox in 1991. He had met Ruth at a Washington prayer breakfast, and the two spent the next several years "promoting prayer study," according to Mike Jaffe of the Society for American Baseball Research. Mizell had a friendly disposition. Writing for Sports Illustrated, Robert Creamer observed, "he has an appealing drawl, a facile tongue, a warm, memorable face and that wonderful nickname." His smiling manner drew comparisons to Preacher Roe. Mizell was good friends with teammate Hal Smith. Both players lived in Florissant, Missouri, and would carpool to Busch Stadium together, often with Wally Moon. Smith and Mizell stayed close friends after their careers had ended. He was also close friends with fellow Christian Don Demeter, whom Mizell struck out in his first MLB at bat. In 1976, he supported fellow former major leaguer Bobby Richardson in his unsuccessful run for a House seat in South Carolina. During his time with the Cardinals, Mizell and Smith attended Florissant Valley Baptist Church, going to the early service so they could make it to Busch Stadium in time for the games. While he was a representative, Mizell attended a Christian and Missionary Alliance church. He never swore, explaining, "I decided a long time ago swearin’ was a waste of words.
SUMOylation Also sumoylation. A type of post-translational modification in which a SUMO protein is conjugated to a polar residue of another protein (usually a lysine) via a covalent isopeptide bond. This effectively tags the second protein, making it distinguishable to other biomolecules and in many cases allowing it to participate in specific reactions or to interact with specific protein complexes. SUMOlyation is closely related to ubiquitination, relying on the same E1/E2/E3 enzymes to transfer SUMO to specific recognition motifs in the target protein, though detaching SUMO depends on SUMO-specific proteases. It plays important roles in numerous cellular processes, including protein localization, transcriptional regulation, stress-response pathways, and cell cycle checkpoints, among others. SUMOlyation is also used in the laboratory as a molecular label and to help solubilize proteins which are difficult to purify.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.